FOR IMMEDIATE RELEASE |
|
OXFORD BIOMEDICA PLC
GENERAL MEETING
Oxford, UK - 6 January 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced the results of its General Meeting held today in London. In accordance with Listing Rule 9.6.18, the following resolution was passed at the meeting:
Resolution 1: THAT, the entry by the Company into the proposed secured Loan Facility of up to £5 million with Vulpes Life Sciences Fund, being a related party transaction for the purposes of the Listing Rules, be and is hereby approved.
The full text of the Shareholder Circular and the Notice of Meeting can be viewed by visiting the Company's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolution passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.
The results of the proxy voting in advance of the meeting are shown below.
Resolution |
Votes For |
Votes at Chairman's Discretion |
Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast |
Result |
|
|
|
|
|
|
|
|
1 |
331,276,628 |
1,016,145 |
981,574 |
718,232 |
716,075 |
334,708,654 |
Approved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: Tim Watts, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications |
Tel: +44 (0)20 7920 2354 |
Notes to editors
1. Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.